ArticleJournal of endocrinological investigation2017
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
Article in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Changes of mRNA expression underlying orbital adipogenesis in thyroid-associated orbitopathy.Archives of medical science : AMS · 2022Article
- Orbital Signaling in Graves' Orbitopathy.Frontiers in endocrinology · 2021Review
- Oxidative Stress in Graves Disease and Graves Orbitopathy.European thyroid journal · 2020Article
- Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.Journal of endocrinological investigation · 2020Article
- Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study.Journal of endocrinological investigation · 2020Article
- Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.Journal of endocrinological investigation · 2020Review
- Teprotumumab: a disease modifying treatment for graves' orbitopathy.Thyroid research · 2020Article
- Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?European journal of endocrinology · 2019Review
- Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.Journal of endocrinological investigation · 2019Article
- Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?Journal of endocrinological investigation · 2019Article
- Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.Frontiers in endocrinology · 2019Review
- Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.Journal of endocrinological investigation · 2018Article
- Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.Journal of infusion nursing : the official publication of the Infusion Nurses SocietyArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28634704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.